Key Highlights

  • Revenue reached USD 114.4 million, up 104% from the year-ago quarter and the highest quarterly level in twelve years.
  • Net income was USD 13.3 million, or USD 0.34 per diluted share, against USD 20.4 million a year earlier.
  • Adjusted EBITDA rose 87% to USD 19.5 million, and Gross Profit rose 54% to USD 27.4 million.
  • Guidance rose to Revenue of USD 382 to 390 million and adjusted EBITDA of USD 59 to 62 million.

Twelve-Year High

Flotek Industries, Inc. (NYSE:FTK) of Houston reported third-quarter 2026 revenue of USD 114.4 million, its highest quarterly level in twelve years, against USD 56.0 million a year earlier, an increase of 104%. Growth was broad-based across the Data Analytics and Chemistry Technologies segments, and Data Analytics revenue itself rose 104%. International Chemistry revenue grew to USD 28.4 million, accounting for 25% of total revenue.

Gross profit rose 54% to USD 27.4 million from USD 17.8 million. Revenue, Net Income and adjusted EBITDA have grown in every quarter of 2026.

Analyst estimates were EPS of USD 0.21 against reported EPS of USD 0.50, and revenue of USD 94.4 million against reported revenue of USD 114.3 million.

Earnings Comparison

Net income was USD 13.3 million, or USD 0.34 per diluted share, compared with USD 20.4 million, or USD 0.53, a decline of 35%. Adjusted EBITDA rose 87% to USD 19.5 million from USD 10.4 million.

For the first nine months, revenue rose 67% to USD 283.8 million, gross profit rose 49% to USD 66.7 million, net income rose 2% to USD 27.9 million, and diluted income per share fell 8% to USD 0.72. Adjusted EBITDA for the nine months rose 84% to USD 45.4 million from USD 24.7 million.

Guidance and Capital Plan

Flotek raised its 2026 guidance for the second time. Total revenues are now projected at USD 382 million to USD 390 million, up from USD 360 million to USD 370 million, and adjusted EBITDA at USD 59 million to USD 62 million, up from USD 50 million to USD 54 million. Guidance does not add back USD 9.3 million of non-cash amortization of contract Assets estimated for the full year.

A term Loan closed in September is intended to fund an expanded Data Analytics capital plan. The company expects 2027 capital expenditures of USD 15 million to USD 20 million, which would exceed its cumulative spending over the past several years, as it pursues applications of its technologies beyond the oil and gas industry.

SG&A expense was USD 8.5 million, or 7% of revenue, versus USD 7.4 million, or 13% of revenue. Revenue tied to the minimum purchase requirements under the long-term Supply agreement was USD 0.9 million versus USD 8.7 million, and third-quarter 2025 net income included a USD 12.6 million non-cash tax benefit.

SG&A expense was USD 8.5 million, or 7% of revenue, versus USD 7.4 million, or 13% of revenue.

Items to Follow

Data Analytics asset expansion, gross Margin recovery and international Chemistry growth are the items to follow, along with how the company funds the planned 2027 capital increase from the term loan proceeds and operating cash flow.